Thrombolytic Care During Inter-hospital Transfer

Study Overview
=================
Brief Summary
-----------------
Evaluation of ischemic stroke patients receiving tissue plasminogen activator (rtPA) during air ambulance transfer

Detailed Description
-----------------
The purpose of our study is to evaluate the effect of air ambulance transport on patients presenting with an ischemic stroke and receive tissue plasminogen activator (rtPA). Primary outcome will be the evaluation of air ambulance transfer and if it leads to protocol violations or significant delays in therapy. Protocol violations include inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight and adverse events (intracranial bleeding, allergic reaction) associated with transfer process. Additional evaluation will include the effects of vibration of the air ambulance and its effects on the lytic activity of rtPA. rtPA is not supposed to be significantly agitated after it is prepared in solution and there is significant vibration and agitation during air ambulance transfer.

Official Title
-----------------
Quality and Effectiveness of Thrombolytic Care During Inter-hospital Transfer (Drip-Ship) With Air Ambulance Services

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Drug: Tissue Plasminogen Activator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who received tissue plasminogen activator for acute ischemic stroke presented directly to comprehensive stroke center or were transferred by our air ambulance service Exclusion Criteria: Transferred by another air ambulance service or ground ambulance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intervention/Transfer<br>Patients who are transferred via air ambulance to a comprehensive stroke center | Drug: Tissue Plasminogen Activator<br> <br> |
| Control<br>Patients presenting directly to the comprehensive stroke center | Drug: Tissue Plasminogen Activator<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With a rtPA Protocol Violation | Protocol violations can include any of the following recorded outcomes: inaccurate dosing or preparation at the outside hospital, uncontrolled blood pressure before and during the flight, unnecessary medication administration before and during the flight, intracranial bleeding, and angioedema | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Time to rtPA |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tissue plasminogen activator